(Q38056640)

English

Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes (English)

1 reference

Europe PubMed Central

27 August 2017

Gram-negative bacteria

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Matthew J. Labreche

1

object named as

Matthew J Labreche

1 reference

Europe PubMed Central

27 August 2017

author name string

Christopher R Frei

2

1 reference

Europe PubMed Central

27 August 2017

publication date

1 November 2012

1 reference

Europe PubMed Central

27 August 2017

American Journal of Health-System Pharmacy

1 reference

Europe PubMed Central

27 August 2017

69

1 reference

Europe PubMed Central

27 August 2017

21

1 reference

Europe PubMed Central

27 August 2017

1863-1870

1 reference

Europe PubMed Central

27 August 2017

The quinolones: past, present, and future

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Fluoroquinolone prescribing in the United States: 1995 to 2002.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Hospital-acquired infections due to gram-negative bacteria

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Population pharmacokinetics of ciprofloxacin in pediatric patients

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Arrhythmias associated with fluoroquinolone therapy

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110464

31 March 2020

Identifiers

10.2146/AJHP110464

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38056640&oldid=2144097541"